Kymera Therapeutics(NASDAQ) KYMR

Market Cap$8.80B

Since IPO (2020)+222%

5 Year+78%

1 Year+143%

1 Month-7%

$103.25

-3.51%

-3.76Today

After hours$103.31+$0.06 (+0.06%)

Kymera Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 107.01	2026-07-30

Kymera Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-3.05%	USD 110.38	2026-07-23
1 month	-6.68%	USD 114.67	2026-06-30
3 month	+32.59%	USD 80.71	2026-05-01
Year to date	+37.53%	USD 77.81	2025-12-31
1 year	+142.82%	USD 44.07	2025-07-30
3 year	+389.08%	USD 21.88	2023-07-31
5 year	+77.82%	USD 60.18	2021-07-30
Since inception	+221.74%	USD 33.26	2020-08-21

Kymera Therapeutics Financials at a Glance

Market Cap

$8.80B

Revenue (TTM)

$51.47M

Net Income (TTM)

-$315.05M

EPS (TTM)

-$3.57

P/E Ratio

-29.97

Dividend

$0.00

Beta (Volatility)

1.64 (High)

Dividend

$0.00

Beta (Volatility)

1.64 (High)

Price

$103.25

Volume

511,581.938

Open

$106.25

Price

$103.25

Volume

511,581.938

Open

$106.25

Previous Close

$107.01

Daily Range

$102.13 - $106.73

52-Week Range

$36.65 - $130.05

Estimated Earnings Date

Aug 10, 2026

Dividend

$0.00

Beta (Volatility)

1.64 (High)

Price

$103.25

Volume

511,581.938

Open

$106.25

Previous Close

$107.01

Daily Range

$102.13 - $106.73

52-Week Range

$36.65 - $130.05

Estimated Earnings Date

Aug 10, 2026

KYMR News

Page 1

KYMR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kymera Therapeutics

Kymera makes oral pills that help the body's natural cleaning system remove disease-causing proteins. These medicines target specific health problems like skin rashes, lung issues, and cancer. They provide a simpler alternative to injections for millions of people worldwide.

What Is Kymera Building?

STAT6 Program: Oral medication designed to treat Type 2 inflammatory diseases like atopic dermatitis, a condition causing itchy skin, and asthma.
IRF5 Program: Small molecule treatments for autoimmune disorders such as lupus, where the immune system attacks the body's own tissues.
IRAK4 Program: Targeted therapies for inflammatory conditions, currently being developed to reach the clinic in 2026.
CDK2 Program: Molecular glue degraders designed to stop tumor growth in cancers like breast cancer and other solid tumors.

Growth and Strategic Moves

Partnered with Sanofi to co-develop IRAK4 degraders, with Sanofi exercising its full participation rights in June 2025.
Entered into an exclusive option and license agreement with Gilead Sciences in June 2025 to develop CDK2 degraders for oncology.
Initiated the BROADEN2 Phase 2b clinical trial for atopic dermatitis and the BREADTH Phase 2b trial for asthma in late 2025.
Started Phase 1 testing for the IRF5 program in healthy volunteers to evaluate safety and drug behavior in the body.

What Makes Kymera Different

The company leads in targeted protein degradation, which removes problematic proteins rather than just blocking them. This catalytic process allows for lower doses and more convenient daily pills compared to traditional injectable biologics.

The Recent Numbers

Gross profit rose to $79 million in Q4 2025, up 968.9% from $7.4 million in Q4 2024.
Revenue fell to $2.9 million in Q4 2025, a 61.3% decrease from $7.4 million in Q4 2024.
Net loss widened to $87 million in Q4 2025, down 23% from a $70.8 million loss in Q4 2024.
Free cash flow was negative $66.9 million in Q4 2025, down 6.6% from negative $62.7 million in Q4 2024.

Bottom Line

Kymera has transitioned from an early research firm into a clinical-stage organization with multiple programs in human testing. Strategic partnerships with global pharmaceutical leaders support its shift toward becoming a fully integrated biotechnology company.

AI Generated • Apr 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

238

CEO

Nello Mainolfi, PhD

Website

www.kymeratx.com

Headquarters

Watertown, MA 02472, US

KYMR Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-697.81%

Net Income Margin

-612.17%

Return on Equity

-25.02%

Return on Capital

-21.02%

Return on Assets

-18.88%

Earnings Yield

-3.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.80B

Shares Outstanding

82.26M

Volume

511.58K

Avg. Volume

796.50K

Financials (TTM)

Gross Profit

$51.47M

Operating Income

-$359.13M

EBITDA

-$306.05M

Operating Cash Flow

-$242.58M

Capital Expenditure

-$1.42M

Free Cash Flow

-$244.00M

Cash & ST Invst.

$650.93M

Total Debt

$80.47M

Kymera Therapeutics Performance Analysis

Kymera Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 46,826,000	-35.7%
2023	2023-12-31	USD 78,592,000	67.8%
2024	2024-12-31	USD 47,072,000	-40.1%
2025	2025-12-31	USD 39,211,000	-16.7%

Kymera Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-48.1%
Q3	2025-09-30	-75.9%
Q4	2025-12-31	3.5%
Q1	2026-03-31	1101.6%

Kymera Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.87	37.5%
2023	2023-12-31	USD -2.52	-12.3%
2024	2024-12-31	USD -2.98	18.5%
2025	2025-12-31	USD -3.69	23.5%

Kymera Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-15.9%
Q3	2025-09-30	1.1%
Q4	2025-12-31	-4.3%
Q1	2026-03-31	27.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$34.37M

+55.5%

Gross Profit

$34.37M

+55.5%

Gross Margin

100.00%

N/A

Market Cap

$8.80B

N/A

Market Cap/Employee

$34.79M

N/A

Employees

253

N/A

Net Income

-$69.23M

-5.6%

EBITDA

-$67.15M

-5.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$650.93M

+40.5%

Total Debt

$80.47M

-6.8%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$66.74M

-8.7%

Short Term Debt

$13.73M

+3.7%

Return on Assets

-18.88%

N/A

Return on Invested Capital

-22.36%

N/A

Free Cash Flow

-$89.27M

-12.1%

Operating Cash Flow

-$88.84M

-12.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CRNXCrinetics Pharmaceuticals, Inc.

CRNXCrinetics Pharmaceuticals, Inc.$83.52-0.13%

PRAXPraxis Precision Medicines, Inc.

PRAXPraxis Precision Medicines, Inc.$307.83+0.03%

IMVTImmunovant, Inc.

IMVTImmunovant, Inc.$38.62-2.18%

ACLXArcellx, Inc.

ACLXArcellx, Inc.$115.07+0.02%

AKROAkero Therapeutics, Inc.

AKROAkero Therapeutics, Inc.$54.65+0.00%

ACADACADIA Pharmaceuticals Inc.

ACADACADIA Pharmaceuticals Inc.$25.87-2.56%

VKTXViking Therapeutics, Inc.

VKTXViking Therapeutics, Inc.$31.74-4.14%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.31+0.01%

Questions About KYMR

What is the current price of Kymera Therapeutics?

Kymera Therapeutics is trading at $103.40 per share.

What is the 52-week range for Kymera Therapeutics?

Over the past 52 weeks, Kymera Therapeutics has traded between $36.65 and $130.05.

How much debt does Kymera Therapeutics have?

As of the most recent reporting period, Kymera Therapeutics reported total debt of $80.47M.

How much cash does Kymera Therapeutics have on hand?

Kymera Therapeutics reported $144.09M in cash and cash equivalents in its most recent financial results.

What is Kymera Therapeutics’s dividend yield?

Kymera Therapeutics does not currently have a dividend yield.

Kymera Therapeutics(NASDAQ) KYMR

Kymera Therapeutics Financials at a Glance

KYMR News

Kymera's CEO Sold $6 Million in Stock After a 170% Run

5 Best Biotech ETFs for 2026 and How to Invest

Why Kymera Therapeutics Stock Popped This Week

Nextech Trims Kymera at a Recent High — think Foolishly before acting.

Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More

Kymera Revenue Drops 55 Percent in Q2

Why Kymera Therapeutics Stock Crushed it This Week

KYMR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Kymera Therapeutics

What Is Kymera Building?

Growth and Strategic Moves

What Makes Kymera Different

The Recent Numbers

Bottom Line

KYMR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Kymera Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KYMR

What is the current price of Kymera Therapeutics?

What is the 52-week range for Kymera Therapeutics?

How much debt does Kymera Therapeutics have?

How much cash does Kymera Therapeutics have on hand?

What is Kymera Therapeutics’s dividend yield?

Premium Investing Services